Latest Breaking News On - Ablative solutions inc - Page 1 : comparemela.com

Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal.

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

This phase 2 randomized trial examines the antihypertensive efficacy and safety of different zilebesiran dosing regimens.

Global Renal Denervation Technologies Strategic Market Report 2023: Market to Reach $2.8 Billion by 2030 - U.S. Market is Estimated at $47 Million, While China is Forecast to Grow at 52.6% CAGR

/PRNewswire/ The "Renal Denervation Technologies - Global Strategic Business Report" report has been added to ResearchAndMarkets.com s offering. Global.

Ablative Solutions, Inc. Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine System™ Kit for Patients with Uncontrolled Hypertension

Ablative Solutions Completes Enrollment in Pivotal Trial of Peregrine Renal Denervation System

April 12, 2023—Ablative Solutions, Inc. announced the completion of patient enrollment in the TARGET BP I study, which is evaluating alcohol-med